Fierce Pharma Biopharma News & Insights
WEB5 days ago · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Pharma | Fierce Pharma
WEB4 days ago · J&J is hitting back after Sanofi's first-line multiple myeloma nod last week with a tranche of positive data on a new Darzalex combo regimen. Fraiser Kansteiner Sep 27, 2024 3:59pm. Connect.
The top 20 drugs by worldwide sales in 2023 | Fierce Pharma
WEBIn 2023, Keytruda’s sales grew 21% at constant exchange rates, reaching $25 billion. At the same time, as GLP-1 diabetes and obesity drugs take the world by storm, Novo Nordisk’s semaglutide ...
Fierce 50 of 2024 | Fierce Pharma
WEBI’m honored to introduce the second edition of the Fierce 50, where we once again spotlight the innovators and leaders driving the future of healthcare, pharma and biotech. This year’s ...
IntraBio hits the ground running with new rare disease launch
WEB18 hours ago · After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch. By Fraiser Kansteiner Sep 30, 2024 3:25pm. IntraBio Aqneursa drug launch rare diseases. With ...
Fierce 50: Breakthroughs honorees - Fierce Pharma
WEBSocial Impact. Patient Advocacy. Innovation. Fierce 50 Gala. Through their tireless efforts, the eight Breakthroughs honorees have improved the lives of countless people around the world. These ...
Special Reports - Fierce Pharma
WEBSep 9, 2024 · Fierce 50 of 2024. Shining a spotlight on the people and companies who are driving meaningful change in healthcare, pharma and biotech. Ayla Ellison Sep 9, 2024 5:02am. Connect.
2021 drug approvals: In a year dominated by COVID, biopharma …
WEBEach year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 ...
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
WEB3 days ago · By Angus Liu Sep 27, 2024 10:15am. Fierce Pharma Asia Daiichi Sankyo Fosun Pharma Yuhan. AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead ...
AstraZeneca plans independent drug supply chains for US and …
WEBMar 27, 2024 · As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another. “We ...